Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASO-DOBLE: Dovato vs Biktarvy Maintenance in HIV
NCT04884139Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL at Week 48. Started Jul 2021; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04884139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884139.